MEDICENNA THERAPEUTICS

Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs) for the treatment of a broad range of cancers. Its proprietary technology platform supports a unique, multi-methodology treatment paradigm that can precisely deliver potent cell-killing agents for cancer as well as actively alter the immunosuppressive tumor micro-environment without harming healthy cells. The company was founded in 2012 and based in Toronto, Ontario, Canada.